Regression of murine lung tumors by the let-7 microRNA

Bitko V, Barik S . (2008). Nasal delivery of siRNA. Methods Mol Biol 442: 75–82.

Bitko V, Musiyenko A, Shulyayeva O, Barik S . (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11: 50–55.

Brown JM, Wilson G . (2003). Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther 2: 477–490.

Calin GA, Liu C-G, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. (2004a). MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 101: 11755–11760.

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004b). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999–3004.

Edinger AL, Thompson CB . (2004). Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16: 663–669.

Esquela-Kerscher A, Johnson SM, Bai L, Saito K, Partridge J, Reinert KL et al. (2005). Post-embryonic expression of C elegans microRNAs belonging to the lin-4 and let-7 families in the hypodermis and the reproductive system. Dev Dyn 234: 868–877.

Esquela-Kerscher A, Slack FJ . (2006). Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269.

Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L et al. (2008). The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759–764.

Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C et al. (2007). Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proc Natl Acad Sci USA 104: 18671–18676.

Isobe T, Herbst RS, Onn A . (2005). Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 32: 315–328.

Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M et al. (2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280–10288.

Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243–3248.

Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D et al. (2007). The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713–7722.

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635–647.

Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005–1017.

Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685–689.

Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA et al. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105: 3903–3908.

Lee YS, Dutta A . (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025–1030.

Levenkova N, Gu Q, Rux JJ . (2004). Gene specific siRNA selector. Bioinformatics 20: 430–432.

Mayr C, Hemann MT, Bartel DP . (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576–1579.

Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D et al. (2004). Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 64: 2307–2316.

Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B et al. (2007). Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6: 2585–2590.

Roush S, Slack FJ . (2008). The let-7 family of microRNAs. Trends Cell Biol 18: 505–516.

Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P et al. (2007). MicroRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67: 9762–9770.

Sevignani C, Calin GA, Nnadi SC, Shimizu M, Davuluri RV, Hyslop T et al. (2007). MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci USA 104: 8017–8022.

Siegfried JM, Krishnamachary N, Gaither Davis A, Gubish C, Hunt JD, Shriver SP . (1999). Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther 12: 291–302.

Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM et al. (2008). Modelling Myc inhibition as a cancer therapy. Nature 455: 679–683.

Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753–3756.

Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N et al. (2009). Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (e-pub ahead of print 8 September 2009).

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.